| |
| |
|
| Insider
Information: |
Benevich Eric |
| Relationship: |
Chief Commercial Officer |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
40,778 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$5,545,400 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
40,778 |
|
|
| Total
Value |
$5,545,400 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
Chief Commercial Officer |
2024-04-15 |
40,778 |
2017-02-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-04-15 |
4 |
AS |
$133.36 |
$2,643,020 |
D/D |
(19,818) |
40,778 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-04-15 |
4 |
OE |
$81.05 |
$1,609,431 |
D/D |
19,818 |
53,365 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-03-14 |
4 |
AS |
$139.38 |
$10,453,418 |
D/D |
(75,000) |
40,778 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-03-14 |
4 |
OE |
$79.02 |
$6,067,628 |
D/D |
75,000 |
110,299 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-02-28 |
4 |
AS |
$134.69 |
$10,101,608 |
D/D |
(75,000) |
40,616 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-02-28 |
4 |
OE |
$43.24 |
$4,025,043 |
D/D |
75,000 |
62,473 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-02-13 |
4 |
AS |
$133.01 |
$146,050 |
D/D |
(1,098) |
40,616 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-02-08 |
4 |
AS |
$134.19 |
$131,509 |
D/D |
(980) |
39,631 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-02-06 |
4 |
AS |
$142.12 |
$181,910 |
D/D |
(1,280) |
38,751 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-01-31 |
4 |
AS |
$140.78 |
$169,927 |
D/D |
(1,207) |
37,601 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2023-08-21 |
4 |
AS |
$107.40 |
$171,836 |
D/D |
(1,600) |
36,436 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2023-02-08 |
4 |
AS |
$104.12 |
$102,036 |
D/D |
(980) |
34,381 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2023-02-07 |
4 |
AS |
$102.29 |
$1,780,868 |
D/D |
(17,390) |
33,501 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2023-02-06 |
4 |
AS |
$105.63 |
$135,201 |
D/D |
(1,280) |
17,879 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2023-01-31 |
4 |
AS |
$109.95 |
$132,710 |
D/D |
(1,207) |
16,729 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2023-01-06 |
4 |
AS |
$125.00 |
$50,000 |
D/D |
(400) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2023-01-06 |
4 |
OE |
$43.24 |
$17,296 |
D/D |
400 |
16,043 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-30 |
4 |
AS |
$125.90 |
$6,295,085 |
D/D |
(50,000) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-30 |
4 |
OE |
$35.99 |
$2,073,275 |
D/D |
50,000 |
35,706 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-10 |
4 |
AS |
$125.36 |
$12,536 |
D/D |
(100) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-10 |
4 |
OE |
$41.78 |
$4,178 |
D/D |
100 |
15,743 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-08 |
4 |
OE |
$41.78 |
$1,027,496 |
D/D |
24,593 |
40,236 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-08 |
4 |
AS |
$125.33 |
$3,082,319 |
D/D |
(24,593) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-03 |
4 |
AS |
$125.02 |
$1,121,183 |
D/D |
(8,968) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-03 |
4 |
OE |
$41.78 |
$374,683 |
D/D |
8,968 |
24,611 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
